2013-03893. Manufacturer of Controlled Substances; Notice of Application; Sigma Aldrich Research Biochemicals, Inc.  

  • Start Preamble

    Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 21, 2012, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760-2447, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following classes of controlled substances:

    DrugSchedule
    Cathinone (1235)I
    Methcathinone (1237)I
    Start Printed Page 12103
    Aminorex (1585)I
    Alpha-ethyltryptamine (7249)I
    Lysergic acid diethylamide (7315)I
    Tetrahydrocannabinols (7370)I
    4-Bromo-2,5-dimethoxyamphetamine (7391)I
    4-Bromo-2,5-dimethoxyphenethylamine (7392)I
    2,5-Dimethoxyamphetamine (7396)I
    3,4-Methylenedioxyamphetamine (7400)I
    N-Hydroxy-3,4-methylenedioxyamphetamine (7402)I
    3,4-Methylenedioxy-N-ethylamphetamine (7404)I
    3,4-Methylenedioxymethamphetamine (MDMA) (7405)I
    Psilocybin (7437)I
    5-Methoxy-N,N-diisopropyltryptamine (7439)I
    1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) (7470)I
    N-Benzylpiperazine (BZP) (7493)I
    Heroin (9200)I
    Normorphine (9313)I
    Amphetamine (1100)II
    Methamphetamine (1105)II
    Nabilone (7379)II
    1-Phenylcyclohexylamine (7460)II
    Phencyclidine (7471)II
    Cocaine (9041)II
    Codeine (9050)II
    Ecgonine (9180)II
    Levomethorphan (9210)II
    Levorphanol (9220)II
    Meperidine (9230)II
    Metazocine (9240)II
    Methadone (9250)II
    Morphine (9300)II
    Thebaine (9333)II
    Levo-alphacetylmethadol (9648)II
    Remifentanil (9739)II
    Carfentanil (9743)II
    Fentanyl (9801)II

    The company plans to manufacture reference standards.

    Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

    Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 22, 2013.

    Start Signature

    Dated: February 8, 2013.

    Joseph T. Rannazzisi,

    Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

    End Signature End Preamble

    [FR Doc. 2013-03893 Filed 2-20-13; 8:45 am]

    BILLING CODE 4410-09-P

Document Information

Published:
02/21/2013
Department:
Drug Enforcement Administration
Entry Type:
Notice
Document Number:
2013-03893
Pages:
12102-12103 (2 pages)
PDF File:
2013-03893.pdf